Riassunto ERYTECH annuncia la registrazione del primo paziente nello studio di fase II di ERY-ASP sul tumore al pancreas

. http://webmdmagazine.wordpress.com About Cyproheptadine without prescription Buy Boniva (Ibandronae Sodium) with free prescription LIONE, Francia--(BUSINESS WIRE)--ERYTECH Pharma (Paris:ERYP) (Euronext Parigi: FR0011471135 - ERYP), la casa biofarmaceutica francese che sviluppa trattamenti innovativi, volti ad "affamare i tumori fino ad annientarli", per la leucemia acuta e altre indicazioni oncogiche rispetto a cui esistono esigenze mediche insoddisfatte, annuncia la registrazione del primo paziente nel suo studio di fase II con ERY-ASP per il trattamento di seconda linea di pazienti affetti dal cancro al pancreas. Tre mesi dopo aver ricevuto l autorizzazione dall ANSM, l autorit`a francese per la sicurezza sui medicinali, `e stato registrato il primo paziente. Dopo aver gi`a completato con successo uno studio di fase I sul tumore al pancreas in stadio avanzato, in cui la tollerabilit`a di ERY-ASP `e stata confermata dai pazienti in questione appartenenti a un segmento molto fragile della popolazione, all inizio di quest anno ERYTECH aveva deciso di continuare a sviluppare il suo prodotto di punta, ERY-ASP, sui tumori solidi, effettuando uno studio di fase II con una terapia di seconda linea per pazienti affetti da tumore al pancreas metastatico progressivo. Il testo originale del presente annuncio, redatto nella lingua di partenza, `e la versione ufficiale che fa fede. Buy Prostate Supplements online Buy Biaxin (Clarithromycin) with free prescription Biaxin (Clarithromycin) with free prescription Le traduzioni sono offerte unicamente per comodit`a del lettore e devono rinviare al testo in lingua originale, che `e l unico giuridicamente valido.

The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014

The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), announce that the cross-border merger between the two companies is legally effective as of 22 July 2014 to create Onxeo, dedicated to orphan oncology diseases. BioAlliance Pharma, as the absorbing entity, will remain admitted to trading on Euronext Paris and will file for approval on the secondary trading and official listing on NASDAQ OMX Copenhagen. The final corresponding calendar will be announced shortly. The company will then operate under the name of Onxeo. Onxeo will aim at becoming a global leader on the fast-growing market of orphan oncology drugs. Biaxin (Clarithromycin) with free prescription It will hold a complementary portfolio of advanced programs targeting severe pathologies for which there is an unmet medical need. Buy Boniva (Ibandronae Sodium) with free prescription Onxeo will offer reinforced market attractiveness, notably towards specialized international investors, through a more important critical mass, a European scale and a portfolio of high added value products. About BioAlliance Pharma Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases. Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. Buy Biaxin (Clarithromycin) with free prescription The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA. BioAlliance Pharma has developed an advanced product portfolio: Orphan Oncology productsLivatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on goingValidive® (Clonidine Lauriad®) (mucositis): Phase II on goingAMEP®/Synfoldin (invasive melanoma): Clinical and Preclinical Phase For more information, visit the BioAlliance Pharma web site at .bioalliancepharma.com About Topotarget Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. About Cyproheptadine without prescription In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to .topotarget.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Buy Prostate Supplements online Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. http://webmdmagazine.wordpress.com BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (.amf-france.org) or on BioAlliance Pharma SA s website (.bioalliancepharma.com).

Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Sage Therapeutics Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABAA receptors in development for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens (super-refractory status epilepticus, or SRSE). SAGE is currently evaluating SAGE-547 in a Phase I/II clinical trial for the treatment of SRSE. Buy Amaryl (Glimepiride) with free Rx Preliminary data indicate that the first four patients enrolled in the clinical trial met the key efficacy endpoint, in that each was successfully weaned off his or her anesthetic agent while SAGE-547 was being administered. Buy Amoxil (Amoxicillin) with no prescription There have also been no reported drug-related serious adverse events in these four patients to date. Sage also recently announced the pricing of an initial public offering of common stock. About Amoxil (Amoxicillin) with no Rx The intended use of proceeds are described in the related prospectus and are expected to include funding pipeline programs including SAGE-547, an intravenous agent that utilizes Ligand’s Captisol® technology, among other purposes. Ligand’s partnership with Sage began in 2011 when the companies entered into a platform Captisol license agreement for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions. About Cosmelite with free Rx Ligand received an upfront payment and is eligible for future milestone payments, product royalties and revenue from the sale of Captisol for use in clinical trials and commercial products. Buy Pain Relief online Elements of the agreement with Sage were expanded in 2014. “Sage illustrates the important role Ligand can play in helping our partners to develop new drug candidates,” said John Higgins, President and Chief Executive Officer of Ligand. http://webmdmagazine.wordpress.com “Whether it’s licensing our technology such as Captisol or our novel research discoveries, by conferring our rights under licenses, new R&D programs can advance efficiently with dedicated resources and funding. Each of these licenses holds potential for new medical and commercial markets to be opened up, with Ligand participating in the economics of a successful program.” About Captisol® Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The original form of Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella at the University of Kansas’ Higuchi Biosciences Center for use in drug development and formulation. This unique technology has enabled six FDA-approved products, including Onyx Pharmaceuticals’ (now Amgen) Kyprolis®, Baxter International’s Nexterone® and Merck’s NOXAFIL® IV. There are more than 30 Captisol-enabled products currently in clinical development. About Status Epilepticus (SE) SE is a life-threatening seizure condition that occurs in approximately 150,000 people each year in the U.S., of which 30,000 SE patients die.1 We estimate that there are 35,000 patients with SE in the U.S. that are hospitalized in the intensive care unit (ICU) each year. An SE patient is first treated with benzodiazepines, and if no response, is then treated with other, second-line, anti-seizure drugs. If the seizure persists after the second-line therapy, the patient is diagnosed as having refractory SE (RSE), admitted to the ICU and placed into a medically induced coma. Currently, there are no therapies that have been specifically approved for RSE; however, physicians typically use anesthetic agents to induce the coma and stop the seizure immediately. After a period of 24 hours, an attempt is made to wean the patient from the anesthetic agents to evaluate whether or not the seizure condition has resolved. Unfortunately, not all patients respond to weaning attempts, in which case the patient must be maintained in the medically induced coma. At this point, the patient is diagnosed as having SRSE. Currently, there are no therapies specifically approved for SRSE About Ligand Pharmaceuticals Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer s disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit .captisol.com for more information on Captisol and .ligand.com for more information on Ligand. Follow Ligand on Twitter @Ligand_LGND. Forward-Looking Statements This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. These forward-looking statements include comments regarding SAGE-547 and other drug candidates, data analysis and evaluation of SAGE-547, utility or potential benefits to patients, Sage’s use of proceeds from its IPO, the potential commercial market for SAGE-547 and plans for continued development and further studies of SAGE-547. Actual events or results may differ from Ligand’s expectations. For example, there can be no assurance that other trials or evaluations of SAGE-547 or other product candidates will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that SAGE-547 or other product candidates will provide utility or benefits to certain patients, that any presentations will be favorably received, that SAGE-547 or other product candidates will be useful, that marketing applications will be filed or, if filed, approved, or that clinical or commercial development of these product candidates will be initiated, completed or successful or that our rights to SAGE-547 and other related product candidates will not be successfully challenged. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand’s stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at .ligand.com as well as in public periodic filings with the Securities and Exchange Commission, available at .sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

GVK BIO lance une nouvelle « marque » en vue de privil'egier le consommateur dans l’offre de services de d'eveloppement clinique

GVK BIO lance une nouvelle « marque » en vue de privil'egier le consommateur dans l’offre de services de d'eveloppement clinique

. http://webmdmagazine.wordpress.com Buy Natural Arthritis Pain Relief online Buy Coaprovel About Zestoretic (Lisinopril HCTZ) without Rx About Viagra Sublingual (Sildenafil Citrate) without Rx About Viagra Professional (Sildenafil Citrate) without Rx

Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country. The MS Visionaries™ program showcases self-starters who have developed programs, tools or services to benefit the MS community. Profiles of these individuals are now featured on Yahoo Health, a new digital magazine covering modern health and wellness topics. Jason Silva, host of National Geographic Channel’s “Brain Games” and renowned technology filmmaker, has partnered with Biogen Idec to underscore the significance of MS Visionaries’ tireless efforts. Buy Duricef (Cefadroxil) without Rx Silva, whose aunt was diagnosed with MS, is using his expertise in technology and innovation to explain what their work could mean for the future of people living with this chronic, often disabling disease. “I believe in the value of ideas. About Effexor (Venlafaxine) When an idea is organized and focused, it can help society in ways beyond what we could ever have imagined,” said Silva. Dostinex (Cabergoline) with no Rx “These MS Visionaries are doing just that by applying their own ideas and influence to make a positive impact on the lives of people with MS.” Yahoo Health will feature weekly stories of MS Visionaries over the next month. Desowen In addition, visitors can read inspiring stories of people living with relapsing forms of MS, who are sharing personal accounts of their experience from diagnosis to treatment on a Biogen Idec therapy. “For almost 40 years, Biogen Idec has been dedicated to improving the lives of people with MS through visionary science and innovative therapies paired with meaningful support and dynamic patient resources,” said Mike Krzan, VP, Patient Services, Biogen Idec. Buy Sports Supplements online “Working with Yahoo Health furthers this mission by providing a national platform to share some of the most current, inspiring contributions by the community, for the community.” MS is a lifelong disease that impacts each person differently. http://webmdmagazine.wordpress.com Every individual has distinct treatment and lifestyle needs driven by the severity of their MS, the impact of disease symptoms, their preferred route of treatment administration, and how the disease affects their daily life. For more information about the MS Visionaries program, click here. About MS VisionariesTM MS Visionaries is a new program developed by Biogen Idec to raise awareness of the inspiring work being done in the area of MS by people in communities across the country. MS Visionaries are selected because they have recognized a challenge facing people with MS and have found a novel way to address the challenge. Beginning in July 2014, new profiles of MS Visionaries are being featured on the new Yahoo Health digital magazine every week. About MS MS attacks the central nervous system (CNS), which is made up of the brain, spinal cord and optic nerves. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The progression, severity and specific symptoms of MS are unpredictable and vary from one person to another. Approximately 2.3 million people are currently living with MS, which includes 400,000 people in the U.S. alone. Of those, approximately 85 percent are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). RRMS is characterized by clearly defined acute attacks with full recovery or with residual deficit upon recovery. About Biogen Idec Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit .biogenidec.com.

Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014

Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014

. About Pyridium (Phenazopyridine) with free Rx ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. About Pletal (Cilostazol) without prescription (NYSE: EBS) will host a conference call at 5:00 pm (Eastern Time) on Thursday, August 7, 2014. Company management will discuss the financial results for the second quarter of 2014, recent business developments, revenue guidance for the third quarter of 2014, and revenue and net income guidance for full year 2014. This conference call can be accessed live by telephone or through Emergent’s website:             Live Teleconference Information: Live Webcast Information: Dial in number: 888-680-0865 Visit .emergentbiosolutions.com (International dial in: 617-213-4853) and select the “Investors” section Passcode: 66947353   Pre-registering for the live call will expedite access and minimize hold times. About Ceftriaxone with free prescription You will be issued a passcode to bypass the operator and connect directly. Buy Incontinence online To pre-register for the call, visit the following website: https://.theconferencingservice.com/prereg/key.process?key=P39XHRA7N A replay will be available from 10:00 pm (Eastern Time) on August 7, 2014 through August 15, 2014.             Replay Information: Webcast Archive: Dial in number: 888-286-8010 Visit .emergentbiosolutions.com (International dial in: 617-801-6888) and select the “Investors” section Passcode: 54320217   About Emergent BioSolutions Inc. Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. http://webmdmagazine.wordpress.com Protonix (Pantoprazole) without prescription Additional information about us may be found at .emergentbiosolutions.com. Follow us on twitter: @emergentbiosolu.

Research and Markets Restless Legs Syndrome Global Clinical Trials Review, H1, 2014

. Buy Hand Cream online About Noroxin (Norfloxacin) with no prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/z64bfd/restless_legs) has announced the addition of the "Restless Legs Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. Our clinical trial report, Restless Legs Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Restless Legs Syndrome clinical trial scenario. http://doctorconsult.wordpress.com Buy Norvasc (Amlodipine) without Rx This report provides elemental information and data relating to the clinical trials on Restless Legs Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Buy Myambutol (Ethambutol) without prescription The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Restless Legs Syndrome. Carbidopa without Rx This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy Understand the dynamics of a particular indication in a condensed manner Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies For more information visit .researchandmarkets.com/research/z64bfd/restless_legs

Research and Markets Essential Overview of the Pharmaceutical Industry Seminar, London - 20th October 2014

Research and Markets Essential Overview of the Pharmaceutical Industry Seminar, London - 20th October 2014

. http://doctorconsult.wordpress.com Buy Levitra Oral Jelly (Vardenafil) DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/rqbrdg/an_essential) has announced the addition of the "An Essential Overview of the Pharmaceutical Industry (Seminar, London)" conference to their offering. 20 October 2014 - The Rembrandt Hotel, London This programme will give you an invaluable overview of the pharmaceutical industry, from discovery of the molecule through development to marketing. Cadecort without prescription About Female Viagra (Sildenafil Citrate) without prescription The drug development process involves a series of lengthy steps that determine the degree of success for every drug brought to the market. Buy General Pet Formulas online Buy Loxitane (Loxapine) with free Rx Decisions made throughout the process affect every aspect of future development and impact heavily on commercialization strategies. This course provides an understanding of the interrelated activities throughout the drug development process and will familiarize participants with the steps involved in developing a drug from Discovery to Commercialization. The course provides a step by step understanding of the main areas of the Pharmaceutical Industry and will also discuss the roles and responsibilities of key staff involved. By giving you a broader high level overview of the pharmaceutical industry as a whole, the course will help you to work more effectively, professionally and to be more motivated in your daily work. BENEFITS OF ATTENDING Increase your Understanding of the Pharma Industry Develop your Knowledge of the Multiple and Complex Stages of Drug Development from Drug Discovery through to Marketing Understand the Roles and Responsibilities of Key Departments and how they Work Together Get to Grips with the Phases of Clinical Trials and Regulatory Processes How to Relate your own responsibilities and Understand the role of Others in the Process Appreciate the Current Trends and Future Prospects for Global Drug Development Agenda How are Drugs Developed? What are the Roles and Responsibilities of the People in the Pharmaceutical Industry/Drug Development? Clinical Trials and How they Advance a Drug to Market Data Management and Statistics Pharmacovigilance Regulatory Processes How are Drugs Marketed and Sold For more information visit .researchandmarkets.com/research/rqbrdg/an_essential

Galderma Unites with Hit Music Artists and PACER’S National Bullying Prevention Center to Raise the Volume around Bullying Prevention

Galderma Unites with Hit Music Artists and PACER’S National Bullying Prevention Center to Raise the Volume around Bullying Prevention

. http://webmdhelper.wordpress.com Buy Echinacea Combos online About Beepen VK Buy Effexor (Venlafaxine) with no Rx Elocon (Mometasone) with no Rx About Eldepryl (Selegiline) with no Rx

Alnylam to Host “RNAi Roundtable” Webcast Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online “RNAi Roundtables” during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the “Alnylam 5x15” programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company’s website, .alnylam.com. About Coumadin (Warfarin) An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event. The RNAi Roundtable topics scheduled to date include: Patisiran and ALN-TTRsc for the treatment of Transthyretin-Mediated Amyloidosis (ATTR) Tuesday, July 15: 12:30 – 2:00 p.m. Buy Cozaar (Losartan) ET Jared Gollob, M.D., Vice President, Clinical Research Moderator: John Maraganore, Ph.D., Chief Executive Officer Guest Speaker: Philip N. Compazine (Prochlorperazine) Hawkins, M.B., B.S., Ph.D., FRCP, Professor of Medicine, National Amyloidosis Centre, University College London Medical School Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates Tuesday, July 22: 11:00 a.m. About Avil without prescription – 12:00 p.m. Buy D-Glucarate online ET Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection Tuesday, July 29: 9:30 – 10:30 a.m. http://webmdhelper.wordpress.com ET Laura Sepp-Lorenzino, Ph.D., Vice President, Entrepreneur-in-Residence Moderator: Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer Guest Speaker: Graham Foster, Ph.D., FRCP, Professor of Hepatology at Queen Mary University of London ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders Thursday, August 7: 9:30 – 10:30 a.m. ET Akin Akinc, Ph.D., Director, Research Moderator: John Maraganore, Ph.D., Chief Executive Officer Guest Speaker: Flora Peyvandi, M.D., Ph.D., Head of the Department of Internal Medicine and Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, University of Milan. ALN-CC5 for the treatment of Complement-Mediated Diseases Wednesday, August 13: 9:30 – 10:30 a.m. ET Benny Sorensen, M.D., Ph.D., Medical Director, Clinical Development Moderator: Barry Greene, President and Chief Operating Officer Guest Speaker: Anita Hill, MBChB (Hons), MRCP, FRCPath, Ph.D., Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK, and Honorary Senior Lecturer at the University of Leeds Alnylam plans to schedule additional RNAi Roundtables covering other pipeline programs to take place in the coming weeks, including ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCSsc for the treatment of hypercholesterolemia; and ALN-AAT for the treatment of AAT deficiency-associated liver disease. The topics, dates, and times of these events will be posted on the Capella section of the company’s website, .alnylam.com/capella. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company’s “Alnylam 5x15TM” product strategy. Alnylam’s genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an RNAi therapeutic targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia; and other programs yet to be disclosed. As part of its “Alnylam 5x15” strategy, as updated in early 2014, the company expects to have six to seven genetic medicine product candidates in clinical development - including at least two programs in Phase 3 and five to six programs with human proof of concept - by the end of 2015. Alnylam is also developing ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection. The company’s demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna Therapeutics, a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit .alnylam.com.

Research and Markets Germany Alopecia Areata Market Highlights - 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/t4sxxk/germany_alopecia) has announced the addition of the "Germany Alopecia Areata Market Highlights - 2014" report to their offering. The latest research, Germany Alopecia Areata Market Highlights - 2014, provides Germany alopecia areata market analysis, competitive landscape, and alopecia areata drug sales forecast in Germany. The research includes Germany alopecia areata market size estimates for 2013, market share forecast for six years to 2019, alopecia areata drugs market share, alopecia areata drugs sales estimates, alopecia areata drugs sales forecast, and alopecia areata late stage pipeline products. This research helps executives track competitor drugs sales and market share in Germany alopecia areata market. It supports decision making in R&D to long term marketing strategies. The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the Germany alopecia areata market. Highlights of the Research: Marketed Alopecia Areata Drugs in Germany Germany Alopecia Areata Market Analysis Alopecia Areata Drugs Sales Analysis in Germany Competitive Landscape in Germany Alopecia Areata market Alopecia Areata Late Stage Pipeline Germany Alopecia Areata Market Forecast Alopecia Areata Drugs Sales Forecast in Germany Future Competitive Landscape Key Topics Covered: 1. Alopecia Areata - Disease Definition 2. About Alesse (Levonorgestrel Bp + Ethinylestradiol Bp) without prescription Marketed Alopecia Areata Drugs in Germany 3. About Allegra (Fexofenadine Hcl) with free prescription Germany Alopecia Areata Market Analysis 3a. Allegra (Fexofenadine) with no Rx Germany Alopecia Areata Market Size 3b. Buy Accuhaler without prescription Drugs Sales in Germany Alopecia Areata Market 4. Buy Allergies for Pets online Competitive Landscape in Germany Alopecia Areata Market 4a. http://webmdhelper.wordpress.com Drugs Market Share in Germany Alopecia Areata Market 4b. Generics Market Share in Germany Alopecia Areata Market 4c. Alopecia Areata Phase 3 Clinical Trial Pipeline Molecules 5. Germany Alopecia Areata Market - Future Market Outlook 5a. Germany Alopecia Areata Market Size Forecast 5b. Drug Sales Forecast in Germany Alopecia Areata Market 5c. Drugs Market Share in Germany Alopecia Areata Market For more information visit .researchandmarkets.com/research/t4sxxk/germany_alopecia